Imaging News and Research

RSS

GE to establish Global Pathology Imaging Centre of Excellence in Ontario

GE announced an agreement to establish its first Global Pathology Imaging Centre of Excellence in Toronto, Ontario. GE and its digital pathology joint venture, Omnyx™, will invest $7.75M along with a $2.25M grant from the Health Technology Commercialization Program created by HTX and funded by the Ontario Ministry of Research and Innovation.

27 Jan 2011

FDA approves Corindus CorPath 200 System for pivotal trial to evaluate safety, effectiveness

Corindus Vascular Robotics, a leading developer of precision vascular robotics, today announced it has been granted Food and Drug Administration conditional Investigational Device Exemption approval to evaluate the safety and effectiveness of its CorPath® 200 System in delivering and manipulating coronary guidewires and stent/balloon systems in percutaneous coronary interventions procedures.

27 Jan 2011

GE's Pathology Imaging Centre of Excellence receives HTX investment under Ontario Flagship Program

HTX announced today an agreement to establish GE's first global Pathology Imaging Centre of Excellence in Toronto, Ontario. GE Healthcare and its digital pathology joint venture, Omnyx™, will invest $7.75M along with a $2.25M grant from the Health Technology Exchange (HTX). Planned collaborative research and development (R&D) partnerships will bring an additional $7.2M, for a total investment of $17.2M over the next 3 years.

27 Jan 2011

AG Mednet's image transfer service surpasses 2 million/month mark

AG Mednet, the world's largest medical image collection and delivery service announced today that the steady state volume of images transferred by its managed service has surpassed the 2 million/month mark. The company achieved impressive growth in utilization in 2010.

25 Jan 2011

UH researchers to discuss computational surgery at MITIE

More than a dozen University of Houston (UH) researchers will be making presentations, ranging from robot-assisted surgery techniques to improving heart and breast surgery procedures, at the third annual international conference in computational surgery Jan. 26-28. The symposium will be held at The Methodist Hospital Research Institute (TMHRI) in Houston.

25 Jan 2011

Taiwanese research team develops large-scale proactive cancer treatment system first-generation prototype

A Taiwanese research team, led by Prof. Ming-Shing Young of Department of Electrical Engineering at National Cheng Kung University (NCKU), has successfully developed a large-scale proactive cancer treatment system first-generation prototype which includes Frequency-Adjustable High Frequency Induction Heating Machine (HFIHM) and 3D Magnetically Guiding Endoscope System (3DMGES).

25 Jan 2011

Study results of Pathwork Diagnostics's Tissue of Origin Test presented at ASCO 2011

Pathwork Diagnostics, Inc., a privately held molecular diagnostics company focused on oncology, announced today that results from a decision impact study of its Tissue of Origin Test were presented this weekend at the ASCO 2011 Gastrointestinal Cancers Symposium in San Francisco.

25 Jan 2011

Patients with chronic depression can benefit from pioneering neurosurgical treatment

Pioneering neurosurgical treatment, a world first in Bristol, which very accurately targets brain networks involved in depression, could help people who suffer with severe and intractable depression.

25 Jan 2011

East Liverpool City Hospital, Foundation Radiology Group enter imaging services agreement

Foundation Radiology Group, the premier provider of diagnostic imaging professional services for community hospitals, is pleased to announce its exclusive imaging services agreement with East Liverpool City Hospital located in East Liverpool, Ohio.

25 Jan 2011

SNM commends FDA Advisory Committee recommendation for florbetapir approval

The Society of Nuclear Medicine (SNM) commends the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee on its recent recommendation for conditional approval of a new imaging agent, florbetapir.

25 Jan 2011

New investigative tool may explore intracellular processes with unprecedented clarity

Nongjian Tao and his colleagues at the Biodesign Institute at Arizona State University have pioneered a new technique capable of peering into single cells and even intracellular processes with unprecedented clarity.

25 Jan 2011

Sleep on it to remember it better: Study

A new study says that the best way to remember something important is to remember it while you are asleep. The research, led by Bjorn Rasch of the University of Basel in Switzerland says that newly learned memories during sleep rather than when awake does a better job of strengthening the memory trace. This could help people with disorders such as post-traumatic stress disorder (PTSD) feel researchers.

24 Jan 2011

UMass Memorial Health Care implements Merge Healthcare's iConnect Access imaging distribution solution

Merge Healthcare, a leading health IT solutions provider, successfully deployed an imaging distribution solution for the physicians of UMass Memorial Health Care, an academic medical center with five facilities serving Central New England. iConnect Access™ gives physicians the ability to view medical images directly from their electronic health record.

24 Jan 2011

Methodist DeBakey Heart & Vascular Center chosen for critical percutaneous heart valve study

The Methodist DeBakey Heart & Vascular Center was chosen today as a site for a critical percutaneous heart valve study. As part of the research study, Methodist physicians will replace diseased cardiac valves through a single, tiny puncture hole in the research subject's groin.

24 Jan 2011

Spectrum submits Post Approval Supplement for removal of bioscan requirement for Indium-111 ZEVALIN

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced that on Thursday, January 20, 2011, it submitted a Post Approval Supplement containing data supporting the removal of the Indium-111 ZEVALIN® pre-treatment imaging evaluation, more commonly referred to as the "bioscan" requirement.

24 Jan 2011

Bayer's gadobutrol injection for CNS imaging receives FDA Advisory Committee approval

Bayer HealthCare Pharmaceuticals Inc. announced today that the Peripheral and Central Nervous System Drugs Advisory Committee to the U.S. Food and Drug Administration voted unanimously that clinical trial and postmarketing data for gadobutrol injection, a macrocyclic 1.0 molar gadolinium-based contrast agent (GBCA), support approval of the product for proposed use in diagnostic magnetic resonance imaging (MRI) in adults and children.

24 Jan 2011

CT scans can help physicians to diagnose abdominal pain, reduce health care costs

The use of CT scanning to evaluate abdominal pain in emergency departments can help physicians arrive at a diagnosis quickly and decisively. A study conducted at Massachusetts General Hospital and appearing in the February issue of the American Journal of Roentgenology also finds that information provided by CT scans changed treatment plans for almost half the patients studied and significantly reduced probable hospital admissions.

24 Jan 2011

Novation, Lantheus Medical to distribute ABLAVAR and DEFINITY diagnostic imaging agents

Lantheus Medical Imaging, a worldwide leader in diagnostic medical imaging, today announced a national contract with Novation for ABLAVAR and DEFINITY Vial For Injectable Suspension, providing increased access to these important diagnostic imaging agents for health care providers served by Novation.

23 Jan 2011

FibroGen announces FG-3019 interim results from phase 1/2 trial against pancreatic cancer

FibroGen, today announced interim results of a phase 1/2 trial of FG-3019, a therapeutic antibody against connective tissue growth factor, in combination with gemcitabine and erlotinib in individuals with unresectable pancreatic cancer.

23 Jan 2011

Immunomedics reports encouraging results from Y-90-labeled clivatuzumab tetraxetan study in pancreatic cancer

Immunomedics, Inc., a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that repeated therapy cycles of its proprietary antibody, clivatuzumab tetraxetan, labeled with yttrium-90 plus low-dose gemcitabine, extended median overall survival.

21 Jan 2011

Imaging News and Research

GE to establish Global Pathology Imaging Centre of Excellence in Ontario

FDA approves Corindus CorPath 200 System for pivotal trial to evaluate safety, effectiveness

GE's Pathology Imaging Centre of Excellence receives HTX investment under Ontario Flagship Program

AG Mednet's image transfer service surpasses 2 million/month mark

UH researchers to discuss computational surgery at MITIE

Taiwanese research team develops large-scale proactive cancer treatment system first-generation prototype

Study results of Pathwork Diagnostics's Tissue of Origin Test presented at ASCO 2011

Patients with chronic depression can benefit from pioneering neurosurgical treatment

East Liverpool City Hospital, Foundation Radiology Group enter imaging services agreement

SNM commends FDA Advisory Committee recommendation for florbetapir approval

New investigative tool may explore intracellular processes with unprecedented clarity

Sleep on it to remember it better: Study

UMass Memorial Health Care implements Merge Healthcare's iConnect Access imaging distribution solution

Methodist DeBakey Heart & Vascular Center chosen for critical percutaneous heart valve study

Spectrum submits Post Approval Supplement for removal of bioscan requirement for Indium-111 ZEVALIN

Bayer's gadobutrol injection for CNS imaging receives FDA Advisory Committee approval

CT scans can help physicians to diagnose abdominal pain, reduce health care costs

Novation, Lantheus Medical to distribute ABLAVAR and DEFINITY diagnostic imaging agents

FibroGen announces FG-3019 interim results from phase 1/2 trial against pancreatic cancer

Immunomedics reports encouraging results from Y-90-labeled clivatuzumab tetraxetan study in pancreatic cancer

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News